TORONTO, Nov. 14, 2011 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) (the "Company") is pleased to announce that it has retained Bay Street
Connect to provide Biosign with financial communications and investor
relations services for up to one year. The service contract with Bay
Street Connect, a Toronto-based company that provides communications
services to public Canadian companies, will focus on positioning
Biosign with the investment community, market analysts and company
Additionally, the Company announced the grant of an aggregate of 750,000
stock options - 350,000 of such options were granted to a director and
an officer of the Company, and 400,000 were granted to Bay Street
Connect, pursuant to the Company's stock option plan. The granted
options expire in 5 years, have an exercise price of $0.385 per share
and are subject to vesting.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of
common health risks associated with blood pressure, life style, and
medication. The core technology combines measurement, analysis, and
rapid knowledge formation to support health monitoring across global
markets. The UFIT® medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information, please visit: www.biosign.com.
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information:
Biosign Technologies Contact:
Dr. Scott Jenkins, CEO
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234